Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

34.29 -33.40 (-49.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 Next >
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE
From The DJS Law Group
Via Business Wire
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Pricing of Upsized $300 Million Public Offering
From uniQure Inc.
Via GlobeNewswire
uniQure Announces $200 Million Proposed Public Offering
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
uniQure to Announce Second Quarter 2025 Financial Results
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET 
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
From uniQure Inc.
Via GlobeNewswire
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
From uniQure Inc.
Via GlobeNewswire
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
uniQure to Announce First Quarter 2025 Financial Results
~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ 
From uniQure Inc.
Via GlobeNewswire
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Pricing of its Public Offering
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Proposed Public Offering
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
From uniQure Inc.
Via GlobeNewswire
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
Via AB Newswire
Topics Intellectual Property
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
From uniQure Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.